After one year collaboration, the PRIME-ROSE consortium has already proceeded with several of our aims and present the concept of clinical data merging from several DRUP-like clinical trials. The PRIME-ROSE network collaboration, consisting of 24 partners across Europe with several ongoing clinical trials, will introduce data also from individual trials. The project, coordinated by Professor Kjetil Taskén from Oslo University Hospital and Hans Gelderblom from Leiden University Medical Center (LUMC), will address key scientific and methodological questions to accelerate broad and equitable access to new and effective cancer treatments across Europe.

PRIME-ROSE consists of individual precision cancer medicine (PCM) DRUP-like clinical trials that will share and aggregate data, having a higher impact on patient care by cross-border collaboration. PRIME-ROSE collaborates closely with the EU4Health project PCM4EU that in particular focuses on precision cancer medicine diagnostics. As the community of the PCM and DRUP-like clinical trials is growing, we are gathering in Barcelona on Saturday evening, September 14th, to discuss ongoing DRUP-like clinical trials and PCM developments therein.

Tina Kringelbach from Copenhagen, Denmark, is coordinating the PRIME-ROSE cohort merging. She will be presenting the PRIME-ROSE poster on Sunday 15^th September.  

“Merging data from several DRUP-like-trials will enable rapid evidence-building and pave the way for the implementation and harmonization of precision oncology across Europe”, says Tina Kringelbach.

‍

DRUP-like clinical trials presented at the ESMO Congress 2024:

All posters are presented in Hall 6 on Sunday, 15^th September at 12:00 – 13:00

o  197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials – Tina M. Kringelbach

o   81P - FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs. Preliminary data after two years of enrollment – Katriina Jalkanen

o   82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE – the national Phase II drug repurposing trial in Finland – Anniina Färkkilä

o   89P - Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: a sub-project of the IMPRESS-Norway trial – Ingrid Dyvik

o   130P - Ipilimumab plus Nivolumab (Ipi+Nivo) in Patients with Tumors harboring High Tumor Mutational Burden or Load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP) – Soemeya F. Haj Mohammad

o   228TiP - FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs – Mika V. Mustonen

o   1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: joint collection and evaluation of real-world evidence – Sahar B. Van Waalwijk van Doorn-Khosrovani

‍

Oral presentations at ESMO 2024:

ESMO Track: The future of cancer via patient expertise in research & innovation projects, Sunday 15^th September at 14:45-16:15, Zaragoza Auditorium – CC5

o  Real world experience & patients' participation in multidisciplinary consortiums: the results from the PRIME-ROSE Community Advisory Board, PRO reporting – Bettina Ryll

‍

Mini oral session: Policy and preventive strategies, Monday 16^th September at 14:45-16:15, Zaragoza Auditorium – CC5

o   1542MO - Mapping the scale of off-label use in oncology: an important step in harmonising access – Hans Timmer

‍

Multidisciplinary session, Monday 16^th September at 16:30-17:45, Santander Auditorium - Hall 5

o  Expanding proteome interrogation to identify early phase clinical trial biomarkers – Janne Lehtiö

‍

‍